Maria Esther Lopes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Esther Lopes has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Anna Bárbara Carneiro-Proietti
Fundação Hemominas, Belo Horizonte, Minas Gerais, Brazil
1 shared publication - Brian Custer
Vitalant Research Institute San Francisco California USA
1 shared publication - Carlos Henrique Valente Moreira
Division of HIV, Infectious Diseases and Global Medicine, University of California San Francisco
1 shared publication - Carolina Miranda Teixeira
Fundação Hemominas, Belo Horizonte, Brazil
1 shared publication Cecília S. Alencar
Laboratório de Medicina Laboratorial LIM 03‐ HCFMUSP São Paulo Brazil
1 shared publication- Cesar de Almeida-Neto
Division of Research & Transfusion Medicine Pro‐Blood Foundation/Blood Center of São Paulo São Paulo Brazil
1 shared publication
Latest Publications
- 4 March 2021
- Published by Wiley in Transfusion Medicine
- Vol. 31 (2) , 104-112
HIV primary drug resistance and associated HIV risk factors among HIV positive blood donors in Brazil from 2007 to 2017
Background Acquisition of HIV primary drug resistant (PDR) infection can lead to poor virologic and clinical outcomes in individuals and hampers public health efforts in epidemic control. Monitoring PDR in HIV‐positive blood donors can be used to inform nationwide trends in the spread of drug‐resistant HIV strains. Methods We conducted a cross‐sectional study using genetic sequence analysis to assess HIV pol sequences, PDR, and risk factors for infection using audio computer‐assisted structured interviews in four large blood centers in Brazil from 2007 to 2017. Results Of 716 HIV‐positive blood donors, 504 (70.4%) were successfully sequenced. HIV clade B (73.2%) was the most prevalent subtype, followed by a mix of non‐B (21.2%) sub‐types. A twofold increase (from 4% to 8%) in recombinants prevalence was observed during the study period. Sixty‐four (12.7%) presented PDR. Overall, HIV PDR prevalence remained stable during the study period. Drug resistance mutations for non‐nucleoside reverse transcriptase inhibitors were found in 39 (7.7%) donors, while for nucleoside reverse transcriptase inhibitors were found in 26 (5.1%), and for protease inhibitors in 24 (4.8%) of HIV‐infected donors. We did not find statistically significant differences in demographics, behavioural risk factors, or HIV genotypes when comparing volunteers with and without PDR. Conclusion The HIV PDR rate among donors remained stable during the study period. HIV‐positive blood donors can be an informative population to monitor primary HIV resistance and ultimately may help to increase the knowledge and awareness of HIV risk factors and PDR.
- 4 March 2021
- Published by Wiley in Transfusion Medicine
- Vol. 31 (2) , 104-112
HIV primary drug resistance and associated HIV risk factors among HIV positive blood donors in Brazil from 2007 to 2017
Background Acquisition of HIV primary drug resistant (PDR) infection can lead to poor virologic and clinical outcomes in individuals and hampers public health efforts in epidemic control. Monitoring PDR in HIV‐positive blood donors can be used to inform nationwide trends in the spread of drug‐resistant HIV strains. Methods We conducted a cross‐sectional study using genetic sequence analysis to assess HIV pol sequences, PDR, and risk factors for infection using audio computer‐assisted structured interviews in four large blood centers in Brazil from 2007 to 2017. Results Of 716 HIV‐positive blood donors, 504 (70.4%) were successfully sequenced. HIV clade B (73.2%) was the most prevalent subtype, followed by a mix of non‐B (21.2%) sub‐types. A twofold increase (from 4% to 8%) in recombinants prevalence was observed during the study period. Sixty‐four (12.7%) presented PDR. Overall, HIV PDR prevalence remained stable during the study period. Drug resistance mutations for non‐nucleoside reverse transcriptase inhibitors were found in 39 (7.7%) donors, while for nucleoside reverse transcriptase inhibitors were found in 26 (5.1%), and for protease inhibitors in 24 (4.8%) of HIV‐infected donors. We did not find statistically significant differences in demographics, behavioural risk factors, or HIV genotypes when comparing volunteers with and without PDR. Conclusion The HIV PDR rate among donors remained stable during the study period. HIV‐positive blood donors can be an informative population to monitor primary HIV resistance and ultimately may help to increase the knowledge and awareness of HIV risk factors and PDR.